Table 1 Characteristics of included studies
Studies | Brennan 2014 [29] | Musiime 2014 [28] | ||
|---|---|---|---|---|
Type of study | Prospective cohort study | Randomised controlled trial | Randomised controlled trial | Retrospective cohort study |
Age range | 5 to 14Â years | 1Â month to 13Â years | 3Â months to 16Â years | 4 to 129Â months |
Countries included | South Africa | Uganda Zambia | Belgium, Brazil, France, Germany, Ireland, Italy, Portugal, Spain and UK | South Africa |
Period of enrollment | April 2009 to March 2011 | May 2010 to September 2013 | January 1998 to July 2000 | August 1998 to April 2013 |
Sample size (n) | 557 | 365 | 130 | 9543 |
Intervention | Abacavir, Lamivudine and Efavirenz | Abacavir, Lamivudine and NNRTI | Abacavir and Lamivudine ± Nelfinavir | Abacavir, Lamivudine and Lopinavir/ritonavir or Efavirenz |
Comparators | Stavudine, Lamivudine and Efavirenz | Zidovudine, Lamivudine and NNRTI | Abacavir and Zidovudine ± Nelfinavir | Stavudine, Lamivudine and Lopinavir/ritonavir or Efavirenz |
Stavudine, Lamivudine and NNRTI | Lamivudine and Stavudine ± Nelfinavir | |||
Length of follow up | Up to 24Â months | Up to 96Â weeks | Up to 5Â years | Up to 48Â weeks |
Funding sources | United States Agency for International Development (USAID) | Medical Research Council UK | European Commission, Medical Research Council, the Istituto Superiore di Sanità , Comunidad Autonoma de, Glaxo-Wellcome and Agouron | National Institutes of Health |